NCT01543802

Study of Preoperative Therapy With Pazopanib (Votrient®) to Treat High-risk Soft Tissue Sarcoma

A Phase II Window-of-opportunity Study of Preoperative Therapy With Pazopanib (Votrient®) in High-risk Soft Tissue Sarcoma

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Heidelberg University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to examine if a short-term treatment with pazopanib, an oral drug inhibiting the growth of blood vessel, can reduce the metabolism of soft-tissue sarcomas and thus facilitate their resection when given prior to surgery. Moreover, the study assesses the prognostic and predictive value of several new biomarkers (endothelial progenitor cells, soluble vascular epithelial growth factor),

Conditions

• Sarcoma, Soft-tissue

Interventions

Type	Name	Description
DRUG	pazopanib	Treatment with pazopanib 800 mg qd for 21 days followed by resection of the tumor after a 7-14 days break

Timeline

• Start date: 2013-04-01
• Primary completion: 2016-10-01
• Completion: 2016-10-01
• First posted: 2012-03-05
• Last updated: 2021-01-26

Locations

4 sites across 1 country: Germany